Search

Your search keyword '"Wirrell EC"' showing total 168 results

Search Constraints

Start Over You searched for: Author "Wirrell EC" Remove constraint Author: "Wirrell EC"
Sorry, I don't understand your search. ×
168 results on '"Wirrell EC"'

Search Results

1. Specific safety and tolerability considerations in the use of anticonvulsant medications in children

2. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice

3. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions

4. International consensus on diagnosis and management of Dravet syndrome

5. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions

6. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions

7. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions

8. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group

9. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome

10. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group.

14. Overview of clinical and physiologic aspects of status epilepticus in the developmental and epileptic encephalopathies.

15. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.

16. Consensus-based recommendations for the diagnosis and treatment of anxiety and depression in children and adolescents with epilepsy: A report from the Psychiatric Pediatric Issues Task Force of the International League Against Epilepsy.

17. An Update on Stiripentol Mechanisms of Action: A Narrative Review.

18. Education Research: EEG Education in Child Neurology and Neurodevelopmental Disabilities Residencies: A Survey of US and Canadian Program Directors.

19. Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel.

20. Pediatric psychogenic non-epileptic seizures: A retrospective observational cohort study at a quaternary center.

21. Clinical presentation and evaluation of epilepsy with eyelid myoclonia: Results of an international expert consensus panel.

22. Drug resistance in epilepsy.

23. A comprehensive narrative review of epilepsy with eyelid myoclonia.

24. How have the recent updated epilepsy classifications impacted on diagnosis and treatment?

25. Temporal Encephalocele: A Treatable Etiology of Drug-Resistant Pediatric Temporal Lobe Epilepsy.

26. Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy.

27. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam.

29. Role of Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) Findings in Early Recognition and Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 Disease.

30. Autism Spectrum Disorder and Epilepsy.

31. Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years.

32. Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease.

33. Inequities in Therapy for Infantile Spasms: A Call to Action.

34. Impact of Antiseizure Medications on Appetite and Weight in Children.

35. International consensus on diagnosis and management of Dravet syndrome.

36. Dravet Syndrome as an Example of Precision Medicine in Epilepsy.

37. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions.

38. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions.

39. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.

40. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.

41. New and emerging pharmacologic treatments for developmental and epileptic encephalopathies.

42. A tale of two cohorts: Differing outcomes in infantile-onset focal epilepsy.

43. Safety and efficacy of responsive neurostimulation in the pediatric population: Evidence from institutional review and patient-level meta-analysis.

44. Masking for School-Age Children With Epilepsy: We Do Have Consensus!

45. Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies.

46. What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?

47. Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort.

48. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.

49. Management of CLN1 Disease: International Clinical Consensus.

50. Cognitive outcome in children with infantile spasms using a standardized treatment protocol. A five-year longitudinal study.

Catalog

Books, media, physical & digital resources